2 citations
,
January 2014 in “Medical Principles and Practice” This study found that patients with rosacea had significantly more radiological evidence of chronic rhinosinusitis, and erythematotelangiectatic severity was associated with CRS.
This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.
50 citations
,
March 2021 in “Journal of investigational allergology & clinical immunology” This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.
March 2026 in “Quality in Sport” This review evaluates photobiomodulation's diverse clinical uses in sports and medicine, reporting physiological modulation and potential therapeutic benefits, but emphasizes the importance of precise dosimetry for success.
72 citations
,
March 2023 in “Biomolecules” This study reviewed the use of dupilumab, beyond its approved indications for atopic dermatitis and prurigo nodularis, and found effective treatment reports for various chronic inflammatory skin diseases such as bullous autoimmune diseases, eczema, and alopecia areata, highlighting its broad potential in dermatology.